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A major disadvantage of conventional amiodarone ther-
apy is the long delay between initiation of therapy and
arrhythmia suppression. In this study, the hypothesis
was tested that complex ventricular arrhythmias would
be suppressed rapidly by an intravenous amiodarone
infusion designed to achieve and maintain a therapeutic
serum concentration. Elevenpatients were studied. Each
underwent a single intravenous dose kinetic study, fol-
lowedby a two stage infusionof amiodarone that achieved
and maintained a serum concentration of 2 to 3 ILg/ml.
ln seven patients, arrhythmias during hours 24 to 48
after the infusion were compared with arrhythmias with-
4IUt therapy. Amiodarone therapy reduced episodes of
ventricular tachycardia by 85% (p < 0.01), paired pre-
mature ventricular complexes by 74% (p < 0.01) and
It has now been clearly established that oral amiodarone is
effecti ve for the suppression of complex ventricular ar-
rhythmias, including recurrent symptomatic ventricular
tachycardia and ventricular fibrillation 0-9), One of the
major disadvahtages of conventional amiodarone therapy is
that, once therapy is initiated, an average of 9,5 days is
required for arrhythmia suppression to occur (5,9). In pa-
tients with recurrent symptomatic ventricular tachycardia or
ventricular fibrillation, such a delay is life-threatening and
in all patients, the delay is inconvenient, psychologically
draining and expensive,
The mechanism of this delay is unknown and may be
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premature ventricular complexes by 60% (p < 0.05).
Four patients could not tolerate a control period without
therapy because of symptomatic arrhythmias. In three
patients, symptomatic arrhythmias were abolished dur-
ing the 24 hour evaluation period. Two of 11 patients,
both with severe left ventricular dysfunction, developed
significant hypotension during the loading phase of the
infusion.
It is concluded that the achievement and maintenance
of a therapeutic serum concentration of intravenous
amiodarone are effectivein the rapid suppression of life-
threatening ventricular arrhythmias. Caution should be
employedwhen using large intravenous doses in patients
with severely impaired left ventricular function.
due, in part, to inadequate loading doses, We have recently
shown (0) that during chronic oral amiodarone therapy
there was a statistically significant reduction in the incidence
of complex ventricular arrhythmias associated with trough
serum amiodarone concentrations greater than 2 JLg/ml as
compared with serum concentrations below this level. Fur-
thermore, we have noted (unpublished observations) that at
initiation of therapy, several days of oral amiodarone at 800
mg/day are required in some patients to achieve this trough
concentration, Therefore, we hypothesized that rapid effec-
tive arrhythmia suppression would result from the admin-
istration of a loading and maintenance infusion of amio-
darone designed to rapidly achieve and then maintain a
therapeutic serum concentration.
To test this hypothesis we studied 11 patients with com-
plex ventricular arrhythmias, including ventricular tachy-
cardia, Each patient underwent a single dose pharmacoki-
netic study, followed by a two stage intravenous infusion
of amiodarone designed to achieve and maintain the serum
amiodarone concentration between 2 and 3 JLg/ml. Arrhyth-
mia suppression was evaluated during the maintenance in-
fusion by a 24 hour two channel electrocardiographic
recording,
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Methods
Study patients. Eleven consecutive patients referred for
amiodarone therapy for refractory complex ventricular ec-
topic rhythms , including ventricular tachycardia , were stud-
ied (Table I). All patients gave written informed consent
as approved by The Committee on Investigation in Humans
of Cleveland Metropolitan General Hospital on November
20, 1981. Arrhythmias were considered refractory when
they failed to be suppressed by procainarnide, quinidine and
disopyramide (used individually) or when these drugs were
contraindicated because of known or potential side effects .
The arrhythmias treated were recurrent symptomatic ven-
tricular tachycardia or ventricular fibrillation in six patients
and asymptomatic, frequent, complex ventricular arrhyth-
mia including nonsustained ventricular tachycardia in five
patients . Seven patients had clinically evident congestive
heart failure and one was receiving dopamine for cardi-
ogenic shock. No patient had severe, primary hepatic or
renal disease.
Study design (Fig. 1). The protocol was as follows.
Before the study, all antiarrhythmic therapy was discont in-
ued for four half-lives. If no symptomatic arrhythmias oc-
curred , a control 24 hour two channel dynamic electrocar-
diogram was performed. If symptomatic arrhythmias occurred,
current antiarrhythmic therapy was restarted and maintained
until the beginning of the loading infusion. Each patient
received (day - 3) a single 5 mg/kg intravenous dose of
amiodarone for approximately 15 minutes. During the next
72 hours, a total of 19 blood samples were obtained at the
following times : 0 (end of infusion), 0.17 , 0.33 , 0.67,1 ,
1.5,2,3 ,4,6,9, 12, 16,20, 24,36,48,60 and 72 hours.
In each case, the pharmacokinetic distribution of the drug
was used to calculate a 12 hour loading infusion and a 36
hour maintenance infusion designed to achieve and maintain
a serum concentration between 2 and 3 p,g/ml. The loading
Table 1. Patient Characteristics
infusion was begun on day 0 , hour 0 and lasted 12 hours.
The first 12 hours of the maintenance infusion (hours 12 to
24) were designed for any dosage adjustments that might
be required to ensure that the serum concentration actually
achieved was within the target range. The last day of the
infusion (hours 24 to 48) was designated as the evaluation
period during which a 24 hour electrocardiogram was ob-
tained to assess the efficacy of the infusion. After the 48
hour infusion, Patients 1 to 6 received oral amiodarone , 800
mg once daily, and Patients 7 to 11 received oral amioda-
rone, 600 to 800 mg twice daily.
Pharmacokinetic data and infusion rates. The data
obtained by sampling blood for 72 hours after the single 5
mg/kg dose of amiodarone on day - 3 was described by
the following four compartment model equation:
where C = concentration, t = time, e = base of natural
logarithms, Ph P3 , P, and P7 = the zero time intercept of
each of the log linear components of the curve and P2 , P4 ,
P6 and Pg = the slopes of each component line. The pa-
rameters PI to Pg were obtained using the standard back-
projection or stripping technique (11). As an example of
the method , the derivation of those parameters from the raw
data for Patient 9 are shown in Table 2. Thus, the zero time
intercepts of compartments I to 4, that is 13.10, 3, 0.56
and 0.12 are parameters PI> P3 , P, and P7 , respectively, and
the slopes of these lines -13 .86, -1.89, -0.1341 and
-0.0154 are parameters P2, P4 , P6 and Pg , respectively.
The half-lives of the four compartments described by this
equation were calculated as tV2 = 0.693/-Pj, where tV2 =
the half-life of each compartment 1 to 4 and Pj = P2, P4'
P6 arid Pg , respectively (12).
After each log-linear component of the curve was ex-
trapolated to true time zero, that is, the beginning of the
Ejection History of Rhythm
Age (yr) Heart Fraction Cardiogenic Requiring History of Drugs
Case &Sex Disease (%) Shock Therapy Cardioversion Failed
I 62M CAD 23 (an) No Sympt VT Yes P,Q,D
2 50M CAD 30 Yes Sympt VT, VF Yes P,Q
3 71M CAD No Syrnpt VT No P,Q,D
4 40F MVP NL No Asympt VT No P,Q,D
5 78M CAD 40 No Sympt VT Yes P,Q,D
6 38F RHD 79 No Asympt VT No P,Q,D
7 70M CM 53 No Asympt VT No P,Q,D
8 58F CAD 21 (an) Yes Syrnpt vr, VF Yes P.Q,D
9 62M CM 27 Yes Asympt VT No P,Q
10 76M CAD 67 No Asympt VT No P,Q,D
II 67M CM 19 Yes Sympt VT, VF Yes P,Q
(an) = aneurysm; Asympt = asymptomatic; CAD = coronary artery disease; CM = cardiomyopathy; D = disopyramide; MVP = mitral valve
prolapse; NL = normal; P = procainamide: Q = quinidine; RHD = rheumatic heart disease; Syrnpt = symptomatic; VF = ventricular fibrillation;
VT = ventricular tachycardia.
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Figure l. Schematic diagram of study protocol. Before the study
(PRE), patients who could tolerate it underwent 24 hours without
antiarrhythmic therapy while a two channel dynamic electrocar-
diogram (CONTROL 24 HR ECG) was obtained. On day - 3.
each patient received a single 5 rug/kg intravenous dose of amio-
darone over 15 minutes (Kinetic Infusion). During the next 72
hours, a total of 19blood samples were obtained at specified times.
Beginning on day 0, a 12 hour loading and then a 36 hour main-
tenance infusion were administered, designed to achieve and then
maintain the serum amiodarone concentration between 2 and 3 JLg/
ml. The first 12 hours of the maintenance infusion was the dosage
adjustment period and the last 24 hours was the evaluation period
during which a second two channel dynamic electrocardiogram
(EVALUATION 24 HR ECG) was obtained to assess the efficacy
of the infusion.
infusion , the area under the completed curve was obtained
by integration and used to approximate clearance from blood
by dividing the dose by the area under the curve .
The maintenance infusion was calculated by multiplying
the des ired concentration at steady state by the clearance
rate (12). The loading. infusion was calculated as Q, = Q2/
( I - eP",), where QI = the loading infusion, Q2 = the main-
tenance infusion, e = the base of the natural logarithms, t =
time and Pg = the slope of the terminal log-linear phase of
the curve obtained from the 72 hour kinetic study (11).
Serum concentrations during the infusion. During the
intravenous infusion, blood was sampled every 6 hours to
document that the serum concentrations were maintained
within the target range and to adjust infusion rates when
necessary.
Arrhythmia suppression. All 24 hour electrocardio-
grams were analyzed on a Camscan superimposition type
dynamic electrocardiogram analyzer (American Optical) and
count s of isolated premature ventricular complexes , paired
premature ventricular complexes and episodes of ventricular
tachycardia were obtained. All counts of single and paired
prematu re ventricular complexes were spot checked by a
technician for accuracy and all episodes of ventricular tachy-
cardia were recorded at a paper speed of 25 mm/s and paper
height ( 11' I mY/lO mm for interval measurement and ver-
ification . Ventricular tachycardi a was defined as three or
PRE -3 -2 -1 0
DAY
Results
Pharmacokinetic data and infusion rates (Table 3). The
half-life of the compartments ranged from 4.2 ± 0.8 min-
utes for the first compartment to 33.6 ± 8.8 hours for the
fourth compartment. The clearance rate ranged from 203 to
438 mllmin. The amount of amiodarone given during the 5
mg/kg single dose kinetic study ranged from 285 (Case II )
to 520 mg (Case 2). The serum concentrations at the end
of the kinetic study (day 0, hour 0 in Fig . I) were insig-
nificant at a mean value of 0.06 u g/ml . This was less than
3% of the target concentration.
The loading infusions of amiodarone calculated from the
phann acokinet ic data ranged from 0.5 to 3.9 rug/min , and
the maintenance infusions from 0.43 to 0.84 mg/min. Thus,
for the 12 hour loading infusions I ,690 ± 669 mg were
administered and for the 36 hour maintenance infusions
IA83 ± 273 mg were administered . The total amount of
amiodaro ne administered to the patients ranged from 1,948
to 4,637 mg over the 48 hour period .
Serum concentrations during the infusion (Fig. 2). The
serum amiodarone concentration averaged 4.39 ± 2.27 JLg/
ml during the loading phase of the infusions and 2.56 ±
0.56 JLg/ml during the maintenan ce infusions (hours 18,24,
30, 36, 42 and 48 hours, respectively). Patients 4 to 10
required no adjustments of the maintenance infusion. Ad-
justments were required in Patients I and 2 because a two
compartment approximation was used to calculate the clear-
ance rather than the four compartment model described.
Adjustments were required in Patient 3 because the second
rather than the fourth log-linear phase of distribution was
used to calculate the loading infusion rate , and in Patient
II because of an adverse reaction (see later ).
Arrhythmia suppression. The results for the seven pa-
tients who tolerated 24 hours without antiarrhythmic therapy
are shown in Figure 3. There was a statistically significant
reduction in the frequency of ventricular tachycardia and in
paired and isolated premature ventricular complexes. The
number of episodes of ventricular tachycardia observed on
the control 24 hour electrocardiogram ranged from II to
31. During the evaluation 24 hour electrocardiogram, there
were zero to seven episodes with three patients demonstrat-
ing complete suppression . The mean percent reduction was
85% (range 64 to 100; probability [p] < 0.0l). There were
64 to 756 episodes of paired premature ventricular com-
more consecutive ventricular ectopic complexes at a heart
rate faster than lOO/min (13) .
Serum amiodarone concentration analysis. Serum was
analyzed for amiodaron e utilizing a high pressure liquid
chromatographic method developed in our laboratory (14).
Statistical analysis. Data are presented as mean ± stan-
dard deviation . The sign test was used to compare control
and evaluation 24 hour electrocardiograms. (15).
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Table 2. Stripping Four Exponentials From a Single Dose Kinetic Study (Patient 9)
Compartment 4 Compartment 3
Raw Data (C = 0.12e - o.OI54' ) Ist Residual (C = 0.56e - O ' 341' ) 2nd Residual
Time Concentration Concentration Concentration Concentration Concentration
(min) ( /-Lg/ml) ( /-Lg /ml) (/-LglmI) (/-Lg/ml) (ug/rn l)
0 16.78 0.12 16.66 0.56 16.10
10 4.60 0.12 4.48 0.55 3.93
20 2.35 0.12 2.23 0.54 L@}40 1.49 0.12 1.37 0.52 0.85
60 1.05 0.12 0.93 0.49 0.44 ®
90 0.77 0.12 0.65 0.46 0. 19
186 0.49 0.12 0.37
238 0.45 0.12 0.33
364 0.35 0.11 0.24 @
542 0.27 0.11 0.16
716 0.24 0.10 0.14
960 0.16 0.10 0.06
1,200 0.09
1,440 0.09
1,844 0.08
2, 160 0.07 @
2,572 0.06
3,606 0.05
4,341 0.03
Compartment 2
(C = 3e - ' 8898' )
Concentration
(ug/rnl)
3.00
2.50
3rd Residual
Concentration
(ug/rnl)
13.1O}<D
1.43
Compartment I
(C = l3 .IDe ·· 'H O')
Concentration
( /-Lg/ml)
13.10
1.43
1st residual = (raw data - compartment 4); 2nd residual = (1st residual - compartment 3); 3rd residual = (2nd residual - compartment 2);
compartment 4 = visually best log-linear line drawn through the terminal portion of the raw data indicated by the bracket labeled @ and extended back
to time = 0 (the end of the infusion); compartment 3 = best log-linear line through the terminal portion of the 1st residual indicated by the bracket
labeled @ and extended to T = 0; compartment 2 = best log-linear line through the terminal portion of the 2nd residual indicated by the brackets
labeled ® and extended to T = 0; compartment I = line defined by the 3rd residual indicated by the bracket labeled <D . T = 0 = end of infusion.
piexes during the control period versus 0 to 191 pairs during
the evaluation period. The average percent reduction was
74% (range 37 to 100; P < 0.01), The mean rate of pre-
mature ventricular complexes was 61 to 539/h during the
control period and 2 to 84/h during the evaluation period.
The mean percent reduction was 60% (range - I to 98; p
< 0.05).
Four patients did not tolerate a control 24 hour electro-
cardiogram when not receiving therapy because of recurrent
ventricular tachycardia or ventricular fibrillation. In Patients
I, 8 and II (Table I), all concurrent antiarrhythm ic therapy
was discontinued at the start of the loading infusion (24
hours before the evaluation period) and in Patient 2, con-
current therapy was discontinued at the start of the evalu-
ation period. In Patient I , recurrence of ventricular tachy-
cardia after the infusion required electrical cardioversion
and reinstitution of bretylium therapy. Patient 2 had no
ventricular tachycardia during the evaluation period , and
Patients 8 and II had only episodes of nonsustained , asymp-
tomatic ventricular tachycardia during this period . All these
patients were maintained near or within the target serum
concentration range throughout the evaluation period.
At the end of the intravenous infusion, treatment with
oral amiodarone, 800 to 1,600 mg/day , was instituted in all
patients. All but Patients 3 and 6 eventually had total
suppression of all ventricular tachycardia after a mean of
5.9 days (range 0 to 24) . The trough amiodarone serum
concentrations at the time of the control study averaged 2.48
j.tg/ml (range 0.86 to 3.18). Patient 3 did not have complete
elimination of all ventricular tachycardia. Patient 6 had an
acute myocardial infarction complicated by pulmonary edema
before complete suppression of ventricular tachycardia and
amiodarone therapy was discontinued. When amiodaron e
therapy was restarted , complete suppression of all ventric-
ular tachycardia was achieved.
The sinus rate slowed gradually from a mean of 77 beats/
min (range 61 to 94) during the control period to a mean
of 60 beats/min (range 47 to 77) at hour 15 of the infusion .
The nadir occurred near the amiodarone concentration peak .
Thereafter, the rate slowly increased and during the eval-
uation period the heart rate averaged 67 beats/min (range
55 to 90).
Adverse reactions. Patient 9. This patient was one
of two patients who had substantial adverse reaction s to the
infusion. He was a 62 year old man with idiopathic cardio-
myopathy who had recently been gradually withdrawn from
dopamine therapy for cardiogenic shock . He had been re-
ferred for therapy of refracto ry asymptomatic, nonsustained
ventricular tachycardia. During the tenth hour of the loading
infusion (after a total of 2,000 mg of amiodarone had been
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Tab le 3. Pharmacokinetic Data and Intra ven ous Amiodarone Infu sion Rates
Compartment Half-Life
2 3 4
t! = 0.693 1 0.693 1 0.693 1 0.693 Loading Maintenance Total
Weight t·, = -- l; = - - t2 =-- CI Infusion Infusion Infusion
-P2 - - P. - P6 - PH
Case (~g) (min) (min) (h) (h) (ml/min) (rug/min) (mg/12h) (mg/min) (mg/36h) (mg/48h)
I ,/0 5.0 22 3.33 31.0 256 1.8 1,318 0.62 1,343 2,661
2 1')4 4.3 30 5.33 53.5 203 1.4 1,026 0.43 922 1,948
3 73 4.0 38 3.25 31.0 222 0.5 351 0.82 1.770 2,121
4 66 2.5 28 3.42 37.5 345 2.6 1,885 0.71 1,528 3,413
5 ;8 5. 1 45 2.83 35.0 423 3.9 2.812 0.84 1.825 4.637
6 71 4.3 50 3.67 25.0 438 3.1 2,204 0.81 1.750 3,954
7 SI 5.0 43 11.33 27.0 230 2.1 1,487 0.57 1,224 2.711
8 68 4.0 25 3.00 20.4 305 2.0 1,469 0.69 1,490 2,959
9 64 3.0 22 5.17 45.0 313 2.8 2.003 0.57 1.235 3,238
10 68 5.0 70 4.75 33.5 429 3.8 2,736 0.82 1.775 4,5 11
II ~ 7 4.0 30 3.50 30.3 304 1.8 1,296 0.67 1,454 2,750
Mean 73 4.2 36.6 4.51 33.6 315 2.3 1,690 0.69 1,483 3,173
± SO 13 0.8 13.9 2.31 8.8 81 1.0 669 0.13 273 848
CI = clearance from blood; Pl , p•. P6 and PH = parameters obtained from the single dose kinetic study; t! = half-life.
infused), the patient 's pulse decreased, blood pressure rap-
idly decreased to 50 mm Hg by Doppler study and he began
vomiting. He was placed in reverse Trendelenburg 's posi-
tion. The amiodarone infusion was stopped and atropine
was administered. When the hypotension and bradycardia
persisted, epinephrine , 0.25 mg, was given intravenously
with immediate restoration of pulse and blood pressure. A
second dose of atropine was given and dopamine therapy
was begun . Inadvertently, the dopamine infusion line be-
came disconnected and the pulse and blood pressure again
decreased, docume nting the atropine-resistant quality of this
problem. During the next 2 hours , the dopamine was dis-
continued. The amiodarone infusion was restarted at the
maintenance rate and the patient tolerated the maintenance
infusion without complications .
Patient 11. This patient , the second patient with an ad-
verse reaction, was a 67 year old man with hypertensive
cardiomyopathy and cardiogenic shock who required amio-
darone therapy for refractory sustained ventricular tachy-
cardia and several episodes of ventricular fibrillation . These
arrhythmias had been refractory to procainamide, quinidine ,
lidocaine and bretylium, but were manageable with over-
drive suppression. A coronary sinus pacemaker was used
to preserve the atrial contribution to cardiac output. Before ,
during and after the infusion , he required dopamine to main-
tain adequate blood pressure and urinary output. At the
eighth hour of the loading infusion. at a time when he had
received a total of 1,200 mg of amiodarone at a rate of 2.5
mg/rmn, blood pressure , urinary output and cardiac output
decreased and pulmonary capillary pressure increased. Tem-
poral) cessation of the amiodarone infusion and the addition
of dobutarnine were required to restore urinary output. After
3 hours, amiodarone infusion was restarted at 1.4 mg/rnin .
Ten hours later , the cardiac output again decreased and the
infusion was stopped. Finally, reinstitution of the infusio n
at 0.6 mg/min was well tolerated for the remainder of the
study. Both of these patients are currently doing well as
outpatient s receiving oral amiodarone therapy.
All infusions were administered through central venous
catheters because intravenous amiodarone can cause phle-
bitis when administered through a peripheral vein; no clin-
ical evidence of phlebitis was noted in our patients.
Discussion
Our results indicate that amiodarone has a rapid onset of
significant antiarrhythmic effect when administered in doses
sufficient to achieve a serum concentration between 2 and
3 p.g/ml. Thus , this study support s the concept that part of
the reported delay in onset of the antiarrhythmic effect of
amiodarone is caused by insufficient loading .
Reports of oral loading doses of amiodar one . The
findings reported by Rakita and Sobol (9) also are consistent
with the notion that inadequate initial doses of amiodarone
result in a longer delay between the initiation of therapy
and effective arrhythmia suppression. They evaluated three
initial oral amiodarone treatment regimens to assess the
relation of the initial dosage to the delay between initiation
of therapy and arrhythmia suppression . They studied 40
patients with recurrent refractory ventricular tachycardia.
With doses of 200 to 800 mg daily, 16.9 ± 9.1 days were
required for suppression of ventricular tachycardia. With
two regimens that used initial doses of 800 to 1,400 mg
daily and 1,400 mg daily, 9 .5 ± 6.4 days and 10.6 ± 5.2
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Figure 2. Amiodarone serum concentrations achieved during the
loading and maintenance infusions. Each patient had blood ob-
tained for serum amiodarone determination every 6 hours during
the loading and maintenance infusions. The results at each time
period are expressed as mean ± standard deviation . The hatched
area represents the target serum amiodarone concentration range.
flexible initial dosage regimen consisting of intravenous and
oral amiodarone in doses of 600 to 2,000 mg daily and
noted a mean delay of 9.5 days between the onset of therapy
and effective arrhythmia suppression. These studies dem-
onstrate the superiority of 800 to 2,000 mg daily regimens
over 200 to 800 mg daily regimens. However, the minimal
time to arrhythmia control was not established in these stud-
ies because neither used side effects or serum concentration
monitoring to define the maximal tolerated oral dose. Our
study employed pharmacokinetic data to guide the admin-
istration of large intravenous doses of amiodarone to rapidly
achieve and then maintain a target serum concentration of
2 to 3 jLg/ml. Utilizing this approach, we were able to
substantially shorten the onset of antiarrhythmic effect.
Comparison with other reports of intravenous load-
ing. The efficacy of intravenous amiodarone reported in
this study is similar to that reported by Morady et al. (16).
They treated 15 critically ill patients with recurrent refrac-
tory symptomatic ventricular tachycardia with intravenous
amiodarone, 5 mg/kg for 15 minutes, followed by the in-
fusion of 0 to 1,000 mg of amiodarone for the next 12 to
24 hours. In II of 15 patients, conventional antiarrhythmic
drugs were also administered. Symptomatic ventricular
tachycardiawas eliminated in 12patients (80%) in the short-
term study. Two patients died from refractory ventricular
tachycardia. Morady et al. (I 6) observed no hypotension or
negative inotropiceffect attributable to amiodarone therapy;
however, the doses they used were substantially less than
those employed in our study. Serum concentrations were
not reported.
Horowitz et al. (17) utilized intravenous plus oral amio-
darone therapy to treat 11 patients with refractory ventricular
tachycardia. They administered amiodarone, 5 to 10 mg/kg
intravenously followed by a continuous infusion of 10 mg/
kg per day and 600 rug/day orally. In all patients, sponta-
neous ventricular tachycardia was eliminated after 72 hours.
The mean serum concentration observed at the end of the
loading infusion (3 to 5 days) was 2.7 j.Lg/ml (range 1.44
to 3.98).
No side effects were observed in either of the studies
described (I6,17 ). In contrast, we noted significant hypo-
tension in two patients, due in one patient to multiple fac-
tors, including bradycardia, vasodilation and probably a
negative inotropic effect and in the other to a documented
negative inotropic effect with a decrease in blood pressure,
an increase of pulmonary capillary pressure, a decrease in
cardiac output and a decrease in urinary flow . The first of
these patients had recently been treated for cardiogenic shock
and had an ejection fraction of 27%. The atropine-resistant
quality of his decompensation is consistent with an arnio-
darone-induced complication (18,19). The second patient
was in cardiogenic shock during the infusion. He had ex-
tremely compromised left ventricular function with an ejec-
tion fraction of 19%. In our study, two of four patients with
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days, respectively, were required for suppression of ven-
tricular tachycardia. The difference between the group reo
ceiving the lower dose and either of the groups receiving
the higher doses was significant (p < 0.05) . Kaski et al.
(5) observed a similar delay treating 23 patients with re-
current sustained ventricular tachycardia. They utilized a
Figure 3. Frequency of ventricular arrhythmias before (Control)
and during (Eval) the amiodarone maintenance infusion. Seven
patients tolerated both a control 24 hour electrocardiogram on no
therapy before receiving any amiodarone and an evaluation 24
hour electrocardiogram during hours 24 to 48 of the maintenance
amiodarone infusion. Thenumber of episodes ofventricular tachy-
cardia per day (left), paired premature ventricular complexes per
day (center) andisolated premature ventricular complexes (PVCs)
per hour (right) that occurred during the control and evaluation
electrocardiograms arecompared for each of these patients. Prob-
ability (p) values were obtained using the sign test.
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a history of cardiogenic shock developed complications dur-
ing the loading infusion.
Mechanism of action. Although intravenous amioda-
rone has a significant antiarrhythmic effect within 24 hours
when administered in doses sufficient to achieve and then
maintain the serum concentration between 2 and 3 JLg/ml,
additional arrhythmia suppression occurred in some patients
with continued oral administration of amiodarone at equiv-
alent serum concentrations .. These data suggest that there
may be two mechanisms of action; one of relatively rapid
onset that may be related to a membrane, cellular or sub-
cellular concentration of drug and a second of slower onset
that may be related to an indirect mechanism such as ac-
cumulation of metabolite or an effect mediated through thy-
roid hormone pathways (20).
Mechanism of side effects. The negative inotropic ac-
tion of intravenous amiodarone therapy observed in this
study has not been seen with oral arniodarone, despite a
large international experience in patients with severe left
ventricular dysfunction (21) . Amiodarone hydrochloride is
insoluble in water. Commercially prepared intravenous
amiodarone (Cordarone) is solubulized with polysorbate 80
(Tween 80). Recently, Gough et al. (22) showed that in-
travenous amiodarone solubulized with polysorbate 80 has
negative inotropic effects in dogs. This negative effect could
be mimicked by administering polysorbate 80 alone in the
same dose and was not seen when the same dose of amio-
darone was administered intravenously using ethanol as the
vehicle . Gough et al. concluded that the agent causing the
negative inotropism was polysorbate 80 and not amioda-
rone . Thus, in our study, the negative inotropic agent may
not be amiodarone but rather the vehicle, polysorbate 80.
Another possibility is that the serum concentrations were
too high during the loading infusions. The fact that both
patients tolerated reinstitution of the infusion at a lower rate
supporr.s the concept that the concentration of either amio-
darone or polysorbate 80 was too high during the loading
infusion. However, in our experience, trough serum amio-
darone concentrations in this range during oral therapy have
been hemodynamically well tolerated . We believe that the
former possibility is more likely .
Significance of pharmacokinetic data. To test the hy-
pothesis that a therapeutic serum concentration would result
in rapid arrhythmia suppression, it was critical that the actual
serum concentrations were within the target range. There-
fore, in the absence of pharmacokinetically derived intra-
venous loading guidelines, we individualized each patient's
loading. and maintenance infusion using data from his own
3 day kinetic study. This approach served two functions .
First, the target serum concentration was achieved in all
patients and, hence, the hypothesis was properly tested.
Second. the pharmacokinetic data themselves were verified
by the tact that their use resulted in the reliable achievement
of the predicted target serum concentration.
A four compartment model was used to analyze the data
obtained from the 3 day single dose kinetic data . We believe
that all the compartments represent distribution into tissue
rather than a combination of distribution and true elimination
from the body, because we sampled blood for several weeks
after similar intravenous single dose kinetic studies in nor-
mal volunteers and found that the terminal phase of elim-
ination was much longer than that observed in any patient
in this study (unpublished observations). Thus, the results
obtained do not define the true body clearance rate of this
unusual drug, but rather the clearance rate from blood during
the period studied, that is, the first 3 days. As we have
proven, this single dose "distribution" clearance is the rel-
evant clearance for intravenous loading over a 2 day period.
From the pharmacokinetic data presented, it is possible
to predict the serum concentrations that would have resulted
from giving the same maintenance infusion dose to all the
patients studied . The clearance rates observed in this study
ranged from 203 to 438 mllmin. Assuming that the mean
infusion rate of 0.7 mg/min had been administered to all
patients, the resulting concentrations at steady state can be
calculated from the equation Css = Q2/CI, where Css = the
concentration at steady state, Q2 = the maintenance infusion
rate and Cl = the clearance from blood (12) . Theoretically
then, the steady state serum concentrations achieved in the
patients in this study would have ranged from 1.6 to 3.4
JLg/ml. Therefore, in the absence of kinetic data, a loading
infusion of 2.3 mg/min for 12 hours , followed by a main-
tenance infusion of 0.7 mg/min for the next 36 hours would
be reasonable in patients without a history of cardiogenic
shock .
Clinical implications. Our results indicate that com-
mercially prepared intravenous amiodarone, in the doses
employed in this study, is rapidly effective for the suppres-
sion of life-threatening ventricular arrhythmias. Utilizing
pharmacokinetic data, a therapeutic serum concentration can
be rapidly and reliably achieved in most patients. In patients
with severe left ventricular dysfunction, caution is required
and close monitoring is imperative.
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